FBXO32 and musculoskeletal system disorder: For musculoskeletal diseases, isoliquiritigenin has been shown to mitigate dexamethasone-induced muscle atrophy by increasing myotube diameters and decreasing expression of Atrogin-1 and MuRF-1 through the Akt/mTOR signaling pathway [41].